Skip to main content
Premium Trial:

Request an Annual Quote

Evonetix Raises $24M in Extended Series B Funding Round

NEW YORK – Synthetic biology company Evonetix said on Tuesday that it has completed a $24 million funding round, extending its total Series B funding to over $54 million.

This round was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures, and Providence also participating and follows Evonetix's £23million ($27.5 million) Series B funding in 2020.

The company plans to use the funds to continue developing its semiconductor chip-based DNA synthesis technology to commercial scale and extend its gene assembly capabilities.

The Cambridge, UK-based company's chips contain numerous reaction sites that enable highly parallel, thermally controlled enzymatic DNA synthesis.

The company launched an early-access program for its DNA synthesis platform in August.

"This substantial investment round demonstrates continued confidence in the progress of our technical development and its potential to revolutionize the accessibility of gene synthesis," Evonetix CEO Colin McCracken said in a statement.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.